Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Embody vs Mint Med

Embody
Graded #52

Lower grade

vs+8.5
Mint Med
Graded #22

Higher grade

The verdict

Mint Med takes it — 84.7/100 to 76.2/100.

Mint Med grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Low both-molecule pricing ($117/$159) and verified — but only 36 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMint Med +3
87
90
Dose & formulationEmbody +3
83
80
Clinical oversightMint Med +2
83
85
Labs & monitoringMint Med +29
54
83
FulfillmentEmbody +11
93
82
Contract termsMint Med +61
25
86
Embody · left barMint Med · right bar

The numbers

MetricEmbodyMint Med
WeighScore76.2/10084.7/100
GradeCB
Scorecard rank#52#22
Semaglutide$79/mo (all doses, promotional rate, compounded)$117/mo
Tirzepatide$129/mo (all doses, promotional rate, compounded)$159/mo
CoverageAll 50 states36 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Embody

Graded #52 · C

Strengths

  • Among the lowest flat rates in the compounded segment — $79/mo semaglutide and $129/mo tirzepatide injection at every dose
  • Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
  • Available in all 50 states with no insurance friction
  • 24/7 unlimited clinician messaging and dose-adjustment support included
  • Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine

Where it loses points

  • The $79 flat rate relies on an auto-applied promo 'locked forever' — list price in the terms is $199/mo and reviewers allege the lock isn't honored
  • Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
  • Pharmacy partners not publicly named — compounding source transparency is limited
  • Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
Mint Med

Graded #22 · B

Strengths

  • $117 sema / $159 tirz
  • LegitScript-verified
  • Both molecules

Where it loses points

  • Only 36 states
  • Injection-only
  • Monitoring detail sparse

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard